Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $4,547.0M | $6,502.0M | $8,216.0M | $8,094.0M | $9,144.0M | $11.5B | $11.5B | $12.8B | $8,148.0M | $3,712.0M | $2,137.0M | $4,114.0M | $4,902.0M | $3,677.0M | $3,387.0M | $2,924.0M | $5,162.0M | $1,056.0M | $3,757.0M | $8,193.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, AstraZeneca PLC's last 12-month Operating Income is $9,201.0M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, AstraZeneca PLC's Operating Income growth was 39.1%. The average annual Operating Income growth rates for AstraZeneca PLC have been 16.4% over the past three years, 21.9% over the past five years.
Over the last year, AstraZeneca PLC's Operating Income growth was 39.1%, which is higher than industry growth of 0.0%. It indicates that AstraZeneca PLC's Operating Income growth is Good.